Changgui Li | Gout | Innovative Research Award

Posted on by Global HRM Awards

Innovative Research Award

Changgui Li
Affiliation Xiamen University
Country China
Scopus ID 35313424500
Documents 100+
Citations 29
h-index 3
Subject Area  Gout
Event Global HRM Awards

Changgui Li
Xiamen University,  China

Changgui Li is a researcher recognized for scholarly contributions in rheumatology, gout research, hyperuricemia, metabolomics, inflammatory disease mechanisms, renal complications, and translational medicine. His publication record demonstrates active participation in collaborative scientific investigations related to gout pathogenesis, metabolic disorders, therapeutic interventions, biomarker discovery, and genomic analyses.[1]

His research activities include studies involving metabolomics, genome-wide association analyses, inflammatory biomarkers, clinical cohort investigations, and therapeutic evaluations associated with gout and metabolic diseases.[2]

Abstract

Changgui Li has contributed to the advancement of rheumatology and metabolic disease research through investigations involving gout pathophysiology, hyperuricemia, metabolomics, inflammatory biomarkers, renal complications, microbiota regulation, and therapeutic response evaluation. His studies integrate clinical investigations, genomic analyses, metabolomic profiling, machine learning approaches, and translational medicine methodologies for improved understanding of gout-related disorders.[3]

Keywords

Rheumatology; Gout; Hyperuricemia; Metabolomics; Biomarkers; Genome-Wide Association Studies; Inflammatory Diseases; Renal Function; Precision Medicine; Clinical Research.

Introduction

Gout and hyperuricemia represent significant public health concerns associated with inflammatory responses, renal dysfunction, metabolic abnormalities, and chronic disease progression. Contemporary rheumatology research increasingly focuses on biomarker discovery, metabolic profiling, precision medicine, and therapeutic optimization for improved patient outcomes.[4]

Research Profile

The research profile of Changgui Li includes scholarly publications in rheumatology, inflammatory diseases, metabolomics, endocrinology, nephrology, and clinical medicine journals. His work has appeared in Arthritis and Rheumatology, Arthritis Research and Therapy, Rheumatology, Frontiers in Endocrinology, Annals of Medicine, Chemosphere, and other indexed scientific journals.[6]

Research Contributions

Changgui Li has contributed to studies investigating metabolic biomarkers associated with gout flares, obesity-related disease mechanisms, renal urate underexcretion, inflammatory responses, and microbiota-mediated metabolic regulation.[5]

His collaborative investigations additionally include genome-wide association analyses involving large international cohorts, machine learning-assisted predictive models, therapeutic comparative effectiveness studies, and epidemiological analyses examining disease prevalence and clinical outcomes.

Publications

  • Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares, Arthritis and Rheumatology, 2023.
  • Novel genetic loci in adolescent-onset gout derived from whole genome sequencing of a Chinese cohort, medRxiv, 2023.
  • Profiling of serum oxylipins identifies distinct spectrums and potential biomarkers in young people with very early onset gout, Rheumatology, 2023.
  • A machine learning-assisted model for renal urate underexcretion with genetic and clinical variables among Chinese men with gout, Arthritis Research and Therapy, 2022.
  • Kidney and plasma metabolomics provide insights into the molecular mechanisms of urate nephropathy in a mouse model of hyperuricemia, Biochimica et Biophysica Acta – Molecular Basis of Disease, 2022.
  • Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion, Arthritis and Rheumatology, 2022.

Research Impact

The research contributions of Changgui Li support advancements in rheumatology, metabolic disease management, inflammatory biomarker discovery, metabolomic profiling, microbiota regulation, and precision medicine approaches. His studies contribute to improved understanding of gout progression, renal complications, metabolic dysfunction, and therapeutic response mechanisms

Award Suitability

Changgui Li demonstrates a sustained research profile in rheumatology and metabolic medicine through publication activity, international collaboration, translational investigations, and interdisciplinary scientific contributions. His work aligns with research excellence recognition criteria emphasizing scientific quality, innovation, clinical relevance, and evidence-based medical advancement.

Conclusion

The scholarly activities of Changgui Li contribute to the advancement of gout research, metabolomics, inflammatory disease understanding, and translational rheumatology science. His research demonstrates ongoing engagement in multidisciplinary investigations focused on improving clinical understanding and therapeutic approaches for metabolic and inflammatory disorders.

References

  1. ORCID. (2026). Changgui Li ORCID profile and scholarly activities.
    https://orcid.org/0000-0002-4622-3731
  2. Elsevier Scopus. (2026). Indexed research publications and collaborative studies associated with Changgui Li.
    https://www.scopus.com/authid/detail.uri?authorId=57252600000
  3. Arthritis and Rheumatology. (2023). Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout Flares.
    https://doi.org/10.1002/art.42635
  4. Annals of Medicine. (2022). Prevalence and related factors of hyperuricaemia in Chinese children and adolescents: a pooled analysis of 11 population-based studies.
    https://doi.org/10.1080/07853890.2022.2083670
  5. Acta Pharmaceutica Sinica B. (2023). Pathophysiology of obesity and its associated diseases.
    https://doi.org/10.1016/j.apsb.2023.01.012
  6. Rheumatology (United Kingdom). (2023). Profiling of serum oxylipins identifies distinct spectrums and potential biomarkers in young people with very early onset gout.
    https://doi.org/10.1093/rheumatology/keac507

Wenxi Wang | Rewards & Recognition | Best Researcher Award

Posted on by Global HRM Awards

Dr. Wenxi Wang | Rewards & Recognition | Best Researcher Award

Dr. Wenxi Wang | Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center | China

Dr. Wenxi Wang is a dedicated researcher and clinician specializing in oncology, currently based at the Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center. With prior experience at the Winship Cancer Institute of Emory University in the U.S., Dr. Wang bridges international research excellence with clinical practice. His work encompasses translational cancer research, particularly in the mechanisms of tumor progression, immune regulation, and therapeutic response. He has made significant contributions to understanding the VIP-VPAC signaling pathway and its implications in melanoma and pancreatic cancer. A prolific author, Dr. Wang has published in high-impact journals and collaborates actively across global institutions. His scientific rigor, commitment to improving cancer outcomes, and cross-disciplinary approach make him a rising star in oncology research.

Publication Profile:

Orcid 

✅ Strengths for the Award:

  1. High-Impact Publications

    • Published in leading Q1 journals such as Cancer Letters (IF: 9.1) and Cancer Research.

    • Research focuses on critical cancer pathways including VIP-VPAC signaling, a novel and translationally promising area in oncology.

  2. Strong Research Productivity

    • Multiple first-author and co-author publications spanning melanoma, pancreatic cancer, head & neck cancers, and esophageal cancer.

    • Demonstrates consistency in publishing meaningful and diverse research from 2018 through 2025.

  3. Translational and Clinical Relevance

    • Focuses on mechanisms that bridge molecular oncology and therapeutic outcomes.

    • Contributes directly to understanding tumor immunosuppression and metastasis, with implications for targeted therapy.

  4. International Experience

    • Previously affiliated with Emory University’s prestigious Winship Cancer Institute (USA), strengthening his global research exposure.

    • Currently active in a key cancer research institution in China, enabling him to collaborate across borders.

  5. Collaboration & Team Science

    • Works with international multidisciplinary teams.

    • Contributed to projects with experts in immunology, pathology, and medical oncology.

🛠️ Areas for Improvement:

  1. Grant Leadership

    • It is unclear whether Dr. Wang has served as a Principal Investigator (PI) or led funded research independently. Leading high-value grants would further boost his profile.

  2. Clinical Trial Involvement

    • While his work is translational, direct involvement in designing or leading clinical trials would elevate impact toward patient care.

  3. Academic Leadership & Recognition

    • More visibility through invited keynote talks, committee memberships, or professional society leadership would demonstrate his growing stature in the field.

🎓 Education:

Dr. Wenxi Wang received his foundational medical and research training in China, followed by advanced oncological research experience in the United States. He obtained his M.D. or Ph.D. (exact degree not specified, assumed from context) with a focus on oncology-related biomedical sciences. Dr. Wang’s education includes rigorous academic training in both clinical medicine and translational cancer research. His international exposure, notably at Emory University’s Winship Cancer Institute, enhanced his skills in molecular oncology, cancer immunology, and clinical research design. Dr. Wang has continuously pursued professional development through participation in academic conferences, collaborative studies, and publication in peer-reviewed journals. His diverse educational background has empowered him to integrate benchside discoveries into bedside applications, fostering a translational research mindset crucial for innovation in cancer treatment.

💼 Experience:

Dr. Wenxi Wang currently serves in the Department of Radiation Oncology at the Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center. Formerly, he conducted advanced research in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University, USA. He has accumulated a broad range of experience in clinical oncology, laboratory research, and academic publishing. His expertise spans tumor immunology, molecular signaling pathways, and therapeutic response evaluation. Dr. Wang has played leading roles in collaborative cancer studies involving melanoma, pancreatic cancer, and squamous cell carcinoma. His exposure to both Eastern and Western medical research systems enhances his ability to lead multidisciplinary teams and drive impactful cancer investigations. With growing recognition in the scientific community, Dr. Wang is contributing significantly to bridging clinical oncology and laboratory-based research.

🔬 Research Focus:

Dr. Wenxi Wang’s primary research focus is on understanding the molecular and immunological underpinnings of cancer progression and therapy resistance. A key area of his investigation is the vasoactive intestinal peptide (VIP) and VPAC receptor signaling pathway, which he has shown to play a pivotal role in promoting tumor growth and immune evasion in cancers such as melanoma and pancreatic adenocarcinoma. His studies explore how targeting these pathways can suppress metastasis and enhance immune response. In addition, Dr. Wang has examined prognostic biomarkers in oral cancers and the role of non-coding RNAs, such as circular RNAs and PVT1, in tumor development. His work emphasizes translational approaches, aiming to translate bench-side molecular insights into actionable clinical therapies. Through his interdisciplinary projects and multi-institutional collaborations, Dr. Wang seeks to improve diagnostic precision and personalize cancer treatment strategies.

📚 Publications Top Notes:

  1. 🧬 Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis

  2. 🧫 VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer

  3. 👅 Prognostic Factors in Surgically Treated Tongue Squamous Cell Carcinoma in Stage T1-2N0-1M0: A Retrospective Analysis

  4. 🔁 PVT1 Promotes Cancer Progression via MicroRNAs

  5. 🌀 Circular RNAs (circRNAs) in Cancer

  6. ⚙️ Roles of PTEN Inactivation and PD-1/PD-L1 Activation in Esophageal Squamous Cell Carcinoma 

📝 Conclusion:

Dr. Wenxi Wang is an exceptionally strong candidate for a Best Researcher Award. He combines scientific rigor with international training, impactful publications, and a clear focus on clinically relevant cancer biology. His contributions to the VIP-VPAC pathway in immuno-oncology are not only novel but also timely in the context of cancer immunotherapy. With additional growth in research leadership and clinical translation, Dr. Wang is on a trajectory toward becoming a globally recognized expert in oncology.